MktsMarkets

Xeris Biopharma Holdings, Inc.
NASDAQ: XERSKey statistics
XERS News
Stories mentioning XERS from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 83,127 | 85,807 | 74,380 | 71,539 | 60,119 | 60,099 | 54,268 | 48,065 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 8,783 | 7,874 | 7,483 | 8,055 | 7,753 | 6,092 | 5,888 | 5,759 |
| Sales General & Admin | 53,144 | 47,502 | 46,459 | 44,393 | 44,018 | 40,139 | 44,969 | 39,993 |
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | 7,916 | 16,773 | 6,731 | 4,482 | (3,090) | 1,679 | (12,893) | (8,187) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | (5,682) | (5,692) | (6,110) | (6,410) | (6,130) | (6,792) | (6,169) | (6,069) |
| Pretax Income | ||||||||
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (3,324) | 749.00 |
| Net Income (Loss) | 2,234 | 11,081 | 621.00 | (1,928) | (9,220) | (5,113) | (15,738) | (15,005) |
| Earnings Per Share (Basic) | 0.01 | 0.07 | 0.00 | (0.01) | (0.06) | (0.03) | (0.11) | (0.10) |
| Earnings Per Share (Diluted) | 0.01 | 0.06 | 0.00 | (0.01) | (0.06) | (0.03) | (0.11) | (0.10) |
| Weighted Average Shares Outstanding (Basic) | 170,523 | 160,425 | 163,650 | 159,459 | 152,446 | 146,773 | 148,994 | 148,346 |
| Weighted Average Shares Outstanding (Diluted) | 177,631 | 172,743 | 177,617 | 159,459 | 152,446 | 146,773 | 148,994 | 148,346 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About XERS
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is a stock listed on the Nasdaq Stock Market under the ticker symbol XERS. It last traded at $15.82 (Nov 9, 2026, 3:32 PM ET), up 4.1% on the day. That gives Xeris Biopharma a market capitalisation of $2.8B.
Over the past 52 weeks XERS has traded between $5.25 and $15.21.
Revenue for the quarter ended Mar 31, 2026 was $83.1M; net income $2.2M. Revenue was up 38.3% from $60.1M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $83.1M | $2.2M | 2.7% |
| Dec 31, 2025 | $85.8M | $11.1M | 12.9% |
| Sep 30, 2025 | $74.4M | $621.0K | 0.8% |
| Jun 30, 2025 | $71.5M | -$1.9M | -2.7% |
From Xeris Biopharma’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…